<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17663" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Anthracyclines</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Venkatesh</surname>
            <given-names>Priyanka</given-names>
          </name>
          <aff>Rajiv Gandhi University ,</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kasi</surname>
            <given-names>Anup</given-names>
          </name>
          <aff>University of Kansas</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Priyanka Venkatesh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anup Kasi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17663.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Anthracyclines are drugs extracted from Streptomyces spp. and used to treat various types of cancers. These agents are among the most effective anticancer drugs to date. This activity reviews the indications, contraindications, activity, adverse events, and other key elements of anthracycline therapy in the clinical setting as relates to the essential points needed by members of an interprofessional team managing the care of patients with the various cancers for which they are indicated.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Summarize the indications for anthracycline therapy in a chemotherapeutic regimen.</p></list-item><list-item><p>Identify the therapeutic mechanism of action of drugs in the anthracycline class.</p></list-item><list-item><p>Outline the potential adverse events profile associated with anthracycline use.</p></list-item><list-item><p>Review interprofessional team strategies for improving care coordination and communication to advance appropriate clinical outcomes with anthracycline chemotherapy for cancer treatment and drive optimal outcomes with the least adverse effects.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17663&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17663">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17663.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Anthracyclines are drugs extracted from <italic toggle="yes">Streptomyces spp.</italic>&#x000a0;used in the treatment of various types of cancers. The different types available for treatment are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Daunorubicin</p>
          </list-item>
          <list-item>
            <p>Doxorubicin</p>
          </list-item>
          <list-item>
            <p>Epirubicin</p>
          </list-item>
          <list-item>
            <p>Idarubicin</p>
          </list-item>
          <list-item>
            <p>Mitoxantrone</p>
          </list-item>
          <list-item>
            <p>Valrubicin</p>
          </list-item>
        </list>
        <p>Anthracyclines are among the most effective chemotherapy agents and cover a significant number of cancers.<xref ref-type="bibr" rid="article-17663.r1">[1]</xref></p>
        <p>
<bold>FDA Approved Indications</bold>
<xref ref-type="bibr" rid="article-17663.r2">[2]</xref>
<xref ref-type="bibr" rid="article-17663.r3">[3]</xref>
<xref ref-type="bibr" rid="article-17663.r4">[4]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute lymphocytic leukemia</p>
          </list-item>
          <list-item>
            <p>Acute myelogenous leukemia</p>
          </list-item>
          <list-item>
            <p>Hodgkin's lymphoma</p>
          </list-item>
          <list-item>
            <p>Non-Hodgkin's lymphoma</p>
          </list-item>
          <list-item>
            <p>Bladder cancer
<list list-type="bullet"><list-item><p>Rapidly recurrent (Ta or Ti) or in situ transitional cell carcinoma (Intravesical therapy)</p></list-item><list-item><p>Neoadjuvant treatment</p></list-item><list-item><p>Metastatic transitional cell bladder cancer</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Breast cancer
<list list-type="bullet"><list-item><p>Adjuvant therapy following axillary lymph node resection in primary breast cancer</p></list-item><list-item><p>Neoadjuvant therapy</p></list-item><list-item><p>Metastatic breast cancer</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Other metastatic cancers
<list list-type="bullet"><list-item><p>Ovarian cancer</p></list-item><list-item><p>Osteogenic sarcoma</p></list-item><list-item><p>Ewing sarcoma</p></list-item><list-item><p>Soft tissue sarcoma</p></list-item><list-item><p>Thyroid cancer</p></list-item><list-item><p>Neuroblastoma</p></list-item><list-item><p>Wilm's tumor</p></list-item><list-item><p>Small cell lung cancer</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Non-FDA Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Advanced endometrial carcinoma</p>
          </list-item>
          <list-item>
            <p>Metastatic hepatocellular cancer</p>
          </list-item>
          <list-item>
            <p>Multiple myeloma</p>
          </list-item>
          <list-item>
            <p>Advanced renal cell carcinoma (with sarcomatoid features)</p>
          </list-item>
          <list-item>
            <p>Thymomas and thymic malignancies</p>
          </list-item>
          <list-item>
            <p>Uterine sarcoma</p>
          </list-item>
          <list-item>
            <p>Waldenstrom macroglobulinemia</p>
          </list-item>
        </list>
        <p>Even though anthracyclines were discovered over 50 years ago, they still see a significant level of use in a number of types of cancers today.<xref ref-type="bibr" rid="article-17663.r5">[5]</xref></p>
      </sec>
      <sec id="article-17663.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The explanations of cytostatic and cytotoxic actions of anthracyclines point to&#x000a0;a number of different mechanisms, including free radical formation, lipid peroxidation, direct membrane effects, and enzyme interactions. The following elucidates some of these theories:</p>
        <p>
<bold>Enzyme Interaction</bold>
</p>
        <p>The most widely accepted explanation for the action of anthracyclines is their interaction with topoisomerase-II. The ternary complex thus formed prevents the re-ligation of the ds-DNA breaks. Subsequently, it promotes growth arrest and apoptotic cell death.<xref ref-type="bibr" rid="article-17663.r6">[6]</xref>&#x000a0;</p>
        <p>
<bold>DNA Intercalation</bold>
</p>
        <p>Anthracyclines have a chromophore moiety that has an intercalating function and inserts between adjacent base pairs of DNA when localized to the cell's nucleus; this inhibits DNA and RNA synthesis, especially in highly replicating cells blocking cell division.<xref ref-type="bibr" rid="article-17663.r6">[6]</xref></p>
        <p>
<bold>Reactive Oxygen Species (ROS)</bold>
</p>
        <p>Redox reactions generate reactive oxygen species in the presence of cytochrome P450 reductase, NADH dehydrogenase, and&#x000a0;xanthine oxidase. The excess ROS cannot be detoxified, resulting in oxidative stress, DNA damage, and lipid peroxidation triggering cell apoptosis.<xref ref-type="bibr" rid="article-17663.r6">[6]</xref></p>
        <p>
<bold>DNA Adduct Formation</bold>
</p>
        <p>These drugs are known to form adducts with DNA promoted by formaldehyde-releasing pro-drugs. The adducts block specific transcription factors and eventually initiate apoptosis.<xref ref-type="bibr" rid="article-17663.r6">[6]</xref></p>
      </sec>
      <sec id="article-17663.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Anthracyclines&#x000a0;administration is generally by injection or&#x000a0;via an intravenous infusion. The type of cancer and its stage will influence&#x000a0;the dose and duration of chemotherapy. As an example, treatment&#x000a0;may be daily for&#x000a0;two weeks followed by an off week to permit the&#x000a0;body to recover and regenerate new cells. This 3-week cycle may then be repeated.&#x000a0;There are&#x000a0;numerous time and administration sequences used; this one given is only an example.&#x000a0;Clinicians need to explain the administration process to the patient so they can understand the schedule, and also receive counsel on factors that may alter the administration regimen.</p>
        <p>
<bold>Mode of Administration</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Injectable</p>
          </list-item>
          <list-item>
            <p>Intravenous</p>
          </list-item>
          <list-item>
            <p>Intraarterial - Not FDA approved for chemotherapy; used for hepatic artery chemoembolization</p>
          </list-item>
          <list-item>
            <p>Intravesical - Used in early bladder cancer</p>
          </list-item>
        </list>
        <p>
<bold>Dosage</bold>
</p>
        <p>The dosing of anthracyclines is by body&#x000a0;surface area and varies with indication and type of anthracycline.&#x000a0;general dose ranges for anthracyclines are listed below; specific indications will vary the dose. Clinicians should consult facility-specific dosing regimens and consult package inserts for specific agents.</p>
        <p>The following shows the dosing regimens for doxorubicin, as an example of how agents in this class may be dosed and administered.</p>
        <p>
<bold>IV Route</bold>
</p>
        <p>
<bold>Acute Lymphoblastic Leukemia</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>60 to 75 mg/m repeated every 21 days as a single agent</p>
          </list-item>
          <list-item>
            <p>40 to 75 mg/m repeated every 21 days if combined with other chemotherapeutic agents</p>
          </list-item>
          <list-item>
            <p>Cumulative dose not to exceed 550 mg/m</p>
          </list-item>
          <list-item>
            <p>The dosing is the same for adults, adolescents, and children</p>
          </list-item>
        </list>
        <p>
<bold>Acute Myelogenous Leukemia</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>60 to 75 mg/m repeated every 21 days as a single agent</p>
          </list-item>
          <list-item>
            <p>40 to 75 mg/m repeated every 21 days if combined with other chemotherapeutic agents</p>
          </list-item>
          <list-item>
            <p>Cumulative dose not to exceed 550 mg/m</p>
          </list-item>
          <list-item>
            <p>The dosing is the same for adults, adolescents, and&#x000a0;children</p>
          </list-item>
        </list>
        <p>
<bold>Hodgkin Lymphoma</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Stanford V regimen</bold>
<list list-type="bullet"><list-item><p>25 mg/m^2 on weeks 1,3,5,7,9, and 11 in combination with mechlorethamine, vinblastine, vincristine, bleomycin, and prednisone. The total duration of treatment is 12 weeks</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>BEACOPP regimen</bold>
<list list-type="bullet"><list-item><p>Adults and adolescents 15 years or older: 25 mg/m on day 1 in combination with bleomycin, etoposide, cyclophosphamide, vincristine, procarbazine, and prednisone</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>ABVD/MOPP regimen</bold>
<list list-type="bullet"><list-item><p>25 mg/m^2 on days 1 and 15 repeated every 28 days in combination with vinblastine, bleomycin, and dacarbazine</p></list-item><list-item><p>It is also used with vinblastine, brentuximab vedotin, and dacarbazine as well.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>The dosing is the same for adults, adolescents, and&#x000a0;children</p>
          </list-item>
        </list>
        <p>
<bold>Intravesical</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Rapidly recurrent (stage Ta or T1) or in situ transitional cell bladder cancer</p>
          </list-item>
          <list-item>
            <p>50 to 150 mg&#x000a0; in 150 ml of normal saline is instilled into the bladder and retained for at least 30 minutes</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17663.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Although anthracyclines are among the most widely used chemotherapeutic agents, their therapeutic potential is limited by their extensive&#x000a0;adverse&#x000a0;event profile, ranging&#x000a0;from mild to severe. The incidence rates of these reactions, however, are largely unknown.<xref ref-type="bibr" rid="article-17663.r7">[7]</xref><xref ref-type="bibr" rid="article-17663.r8">[8]</xref></p>
        <p>
<bold>Mild</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Chills - Rapid</p>
          </list-item>
          <list-item>
            <p>Urticaria - Rapid</p>
          </list-item>
          <list-item>
            <p>Pruritis - Rapid</p>
          </list-item>
          <list-item>
            <p>Injection site reaction - Rapid</p>
          </list-item>
          <list-item>
            <p>Rash&#x000a0;-&#x000a0; Early&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Infection -&#x000a0; Early</p>
          </list-item>
          <list-item>
            <p>Nausea and vomiting&#x000a0;-&#x000a0; Early</p>
          </list-item>
          <list-item>
            <p>Fever&#x000a0;-&#x000a0; Early</p>
          </list-item>
          <list-item>
            <p>Diarrhea&#x000a0;-&#x000a0; Early</p>
          </list-item>
          <list-item>
            <p>Abdominal pain&#x000a0;-&#x000a0; Early</p>
          </list-item>
          <list-item>
            <p>Urine discoloration&#x000a0;-&#x000a0; Early</p>
          </list-item>
          <list-item>
            <p>Lacrimation&#x000a0;-&#x000a0; Early</p>
          </list-item>
          <list-item>
            <p>Malaise&#x000a0;-&#x000a0; Early</p>
          </list-item>
          <list-item>
            <p>Anorexia - Delayed</p>
          </list-item>
          <list-item>
            <p>Photosensitivity&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Nail discoloration&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Skin hyperpigmentation&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Amenorrhea&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Oligospermia&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Azoospermia&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Gonadal suppression&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Spermatogenesis inhibition&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Asthenia&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Co-enzyme Q10 deficiency&#x000a0;- Delayed</p>
          </list-item>
        </list>
        <p>
<bold>Moderate</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bleeding - Early</p>
          </list-item>
          <list-item>
            <p>Bone marrow suppression&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Neutropenia&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Dehydration&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Stomatitis&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Esophagitis&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Colitis&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Erythema&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Palmar-plantar erythrodysesthesia&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Conjunctivitis&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Phlebitis&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Skin ulcer&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Radiation recall reaction&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Skin ulcer&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Elevated hepatic enzymes&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Peripheral neuropathy&#x000a0;- Delayed</p>
          </list-item>
        </list>
        <p>
<bold>Severe</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Anaphylactoid reactions&#x000a0;-&#x000a0;Rapid</p>
          </list-item>
          <list-item>
            <p>Tissue necrosis - Early&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Coma - Early</p>
          </list-item>
          <list-item>
            <p>Leukopenia&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Thrombocytopenia&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Heart Failure&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Cardiomyopathy&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Cardiotoxicity&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Pericarditis&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Myocarditis&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Typhlitis&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Peptic ulcer&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>GI bleeding&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Keratitis&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Tumor lysis syndrome&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>New primary malignancy&#x000a0;- Delayed</p>
          </list-item>
          <list-item>
            <p>Seizures&#x000a0;- Delayed</p>
          </list-item>
        </list>
        <p>Researchers are studying ways to mitigate the toxicity of anthracyclines through newer technologies, including nanoparticle delivery systems.<xref ref-type="bibr" rid="article-17663.r5">[5]</xref><xref ref-type="bibr" rid="article-17663.r9">[9]</xref><xref ref-type="bibr" rid="article-17663.r10">[10]</xref>&#x000a0;The effectiveness of cardioprotective agents remains ambiguous; there is no high-quality evidence supporting their effectiveness.<xref ref-type="bibr" rid="article-17663.r10">[10]</xref></p>
      </sec>
      <sec id="article-17663.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Relative Contraindications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Anthracycline hypersensitivity
<list list-type="bullet"><list-item><p>Patients with previous anaphylactic reactions following administration of anthracyclines</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Hepatic disease
<list list-type="bullet"><list-item><p>Patients with severe hepatic disease, defined as Child-Pugh class C or serum bilirubin greater than 5 mg/dL. Dosage adjustments are necessary for patients with mild to moderate hepatic&#x000a0;disease.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Pre-existing cardiac conditions
<list list-type="bullet"><list-item><p>Heart failure, cardiomyopathy, myocardial infarction, myocarditis, pericarditis</p></list-item><list-item><p>Assessment of cardiac function using a MUGA or echocardiogram is necessary before starting treatment in these patients.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Gender
<list list-type="bullet"><list-item><p>Females have a higher risk of anthracycline-induced cardiotoxicity</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Age
<list list-type="bullet"><list-item><p>Children and adolescents have a higher risk of developing late cardiovascular dysfunction. They should receive periodic cardiac evaluations.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Reports of prepubertal growth inhibition/failure and gonadal impairment in children and adolescents</p>
          </list-item>
          <list-item>
            <p>Pregnancy (category D)</p>
          </list-item>
          <list-item>
            <p>In animal studies</p>
          </list-item>
          <list-item>
            <p>Breastfeeding&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Live vaccines</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17663.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>
<bold>Maximum Dosage</bold>
</p>
        <p>
<bold>Adults, Adolescents and, Children</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Doxorubicin - Maximum lifetime cumulative dose of 550 mg/m; 450 mg/m^2 in patients who have received previous mediastinal radiation</p>
          </list-item>
          <list-item>
            <p>Daunorubicin - 45 mg/m/dose IV (up to&#x000a0;90 mg/m/dose has been used off-label);&#x000a0;Maximum lifetime cumulative dose of 550 mg/m^2; 450 mg/m^2 in patients who have received previous mediastinal radiation.</p>
          </list-item>
          <list-item>
            <p>Epirubicin - 150 mg/m/dose&#x000a0; as a single agent - maximum cumulative dose is&#x000a0; 900mg/m^2.</p>
          </list-item>
          <list-item>
            <p>Valrubicin - 800 mg intravesically in adults - efficacy and safety not established in adolescents and children</p>
          </list-item>
          <list-item>
            <p>Idarubicin - 12 mg/m^2 IV; maximum cumulative&#x000a0; lifetime dose is 150 mg/m^2 - efficacy and safety not established in adolescents and children</p>
          </list-item>
          <list-item>
            <p>Mitoxantrone - Maximum cumulative lifetime dosage is 140 mg/m^2</p>
          </list-item>
        </list>
        <p>
<bold>Children with BSA less than 0.5 m should have dose calculated based on body weight.</bold>
</p>
        <p>
<bold>Dose adjustments are necessary for hepatic impairment.</bold>
</p>
        <p>
<bold>Drug Interactions</bold>
</p>
        <p>Anthracyclines are major substrates of CYP2D6 and CYP3A4.&#x000a0;Caution is necessary when using them concurrently with inhibitors of CYP3A4 and CYP2D6, as this will reduce anthracycline clearance and increase the chances of cardiotoxicity and other adverse effects. Notable interactions exist with taxanes (except docetaxel) and trastuzumab.<xref ref-type="bibr" rid="article-17663.r11">[11]</xref><xref ref-type="bibr" rid="article-17663.r12">[12]</xref></p>
      </sec>
      <sec id="article-17663.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Anthracycline-Induced Cardiotoxicity</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Cardiotoxicity-induced by anthracyclines is a significant cause of morbidity and mortality. The clinical definition is new-onset heart failure and/or detection of left ventricular dysfunction in exposed individuals; LV ejection fraction is the most commonly used measure.<xref ref-type="bibr" rid="article-17663.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Patients at high risk are those receiving any of the following treatments -
<list list-type="bullet"><list-item><p>High dose anthracyclines (e.g., doxorubicin greater than 250 mg/m), high dose radiation therapy (greater than 30 Gy) where the heart is in the radiation field and, lower dose anthracyclines in combination with lower-dose radiation therapy.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Other risk factors - Age older than 60 years at cancer diagnosis, compromised cardiac function, multiple cardiovascular risk factors including smoking, hypertension, hyperlipidemia and, obesity.<xref ref-type="bibr" rid="article-17663.r13">[13]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Antidotes for Anthracyclines</bold>
</p>
        <p>Tissue necrosis induced by the extravasation of anthracycline can have many complications. Dexrazoxane is an available antidote to tackle the effects of extravasation and may also help prevent the development of anthracycline-induced cardiotoxicity.<xref ref-type="bibr" rid="article-17663.r14">[14]</xref><xref ref-type="bibr" rid="article-17663.r15">[15]</xref></p>
      </sec>
      <sec id="article-17663.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The administration of anthracyclines requires the efficient functioning of an interprofessional healthcare team comprised of doctors and other health professionals. A general practitioner, oncologist, physician assistant or nurse practitioner, pharmacist, and nurses are usually involved in the patient's care. A pediatrician and cardiologist may also have involvement as the case may dictate. The primary oncologist usually decides the patient's treatment plan;&#x000a0;they will also counsel the patient on the need for this chemotherapeutic agent and the potential risks. During the initial treatment phase, a pharmacist is usually involved in providing the patient information on the dose, adverse effects, monitoring, checking for possible drug interactions, and follow-up.</p>
        <p>After the initial phase of treatment, the patient is regularly followed up in the oncology clinic by the oncologist, who assesses response to treatment and also monitors the patient for adverse effects. The oncologist may alternate with the physician assistant or the nurse practitioner to see the patient at shorter intervals. A pediatrician may monitor growth and development in cases of chemotherapy in children. Oncology certified nursing will administer the medication and must be aware of the signs of toxicity or adverse effects so they can effectively monitor the patient and report any issues to the clinician on duty or oncologist. These examples demonstrate the impact of an interprofessional team on patient care, driving outcomes to a positive result while minimizing adverse events.</p>
        <p>The most critical component of an interprofessional approach is the involvement of a cardiovascular team in the treatment to prevent anthracycline-induced&#x000a0;cardiotoxicity and manage it effectively. Several studies have shown the benefit of this approach, including long-term care and follow-up in the outpatient setting. One such study provides high-level evidence for the development of guidelines.<xref ref-type="bibr" rid="article-17663.r16">[16]</xref>&#x000a0;Interprofessional care coordination will derive the best patient outcome while minimizing the not insignificant potential adverse events of anthracycline therapy. [Level 5]</p>
      </sec>
      <sec id="article-17663.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17663&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17663">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17663/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17663">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17663.s11">
        <title>References</title>
        <ref id="article-17663.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Minotti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Menna</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Salvatorelli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cairo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gianni</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.</article-title>
            <source>Pharmacol Rev</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>56</volume>
            <issue>2</issue>
            <fpage>185</fpage>
            <page-range>185-229</page-range>
            <pub-id pub-id-type="pmid">15169927</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17663.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meg&#x000ed;as-Vericat</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Cuadr&#x000f3;n</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sanz</surname>
                <given-names>M&#x000c1;</given-names>
              </name>
              <name>
                <surname>Poveda</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Montesinos</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.</article-title>
            <source>Expert Rev Clin Pharmacol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>197</fpage>
            <page-range>197-218</page-range>
            <pub-id pub-id-type="pmid">30672340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17663.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antol&#x000ed;n</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Acea</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Albaina</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Concha</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>Santiago</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Caballero</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mosquera</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Varela</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Soler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Calvo</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution.</article-title>
            <source>Breast Cancer (Dove Med Press)</source>
            <year>2019</year>
            <volume>11</volume>
            <fpage>29</fpage>
            <page-range>29-42</page-range>
            <pub-id pub-id-type="pmid">30643452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17663.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seetharam</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>First-Line Therapy for Metastatic Soft Tissue Sarcoma.</article-title>
            <source>Curr Treat Options Oncol</source>
            <year>2019</year>
            <month>Jan</month>
            <day>24</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <pub-id pub-id-type="pmid">30675651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17663.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McGowan</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Maulik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Piotrowska</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Yellon</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Anthracycline Chemotherapy and Cardiotoxicity.</article-title>
            <source>Cardiovasc Drugs Ther</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <page-range>63-75</page-range>
            <pub-id pub-id-type="pmid">28185035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17663.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tomiyasu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Imatinib enhances the anti-tumour effect of doxorubicin in canine B-cell lymphoma cell line.</article-title>
            <source>Vet J</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>254</volume>
            <fpage>105398</fpage>
            <pub-id pub-id-type="pmid">31836165</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17663.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Avila</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Siqueira</surname>
                <given-names>SRR</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>SMA</given-names>
              </name>
              <name>
                <surname>Bocchi</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Prevention and Treatment of Chemotherapy-Induced Cardiotoxicity.</article-title>
            <source>Methodist Debakey Cardiovasc J</source>
            <year>2019</year>
            <season>Oct-Dec</season>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>267</fpage>
            <page-range>267-273</page-range>
            <pub-id pub-id-type="pmid">31988687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17663.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jurczak</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>D&#x00142;ugosz-Danecka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Szmit</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cardio-oncology for better lymphoma therapy outcomes.</article-title>
            <source>Lancet Haematol</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>e273</fpage>
            <page-range>e273-e275</page-range>
            <pub-id pub-id-type="pmid">32135129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17663.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cagel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grotz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bernabeu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Moretton</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Chiappetta</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Doxorubicin: nanotechnological overviews from bench to bedside.</article-title>
            <source>Drug Discov Today</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>270</fpage>
            <page-range>270-281</page-range>
            <pub-id pub-id-type="pmid">27890669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17663.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mukai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kogawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matsubara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Naito</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sasaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hosono</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A first-in-human Phase 1 study of epirubicin-conjugated polymer micelles (K-912/NC-6300) in patients with advanced or recurrent solid tumors.</article-title>
            <source>Invest New Drugs</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>307</fpage>
            <page-range>307-314</page-range>
            <pub-id pub-id-type="pmid">28054329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17663.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gianni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vigan&#x000f2;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Locatelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Capri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Giani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tarenzi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bonadonna</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.</article-title>
            <source>J Clin Oncol</source>
            <year>1997</year>
            <month>May</month>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>1906</fpage>
            <page-range>1906-15</page-range>
            <pub-id pub-id-type="pmid">9164201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17663.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ewer</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Ewer</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction.</article-title>
            <source>J Clin Oncol</source>
            <year>2010</year>
            <month>Sep</month>
            <day>01</day>
            <volume>28</volume>
            <issue>25</issue>
            <fpage>3901</fpage>
            <page-range>3901-4</page-range>
            <pub-id pub-id-type="pmid">20679626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17663.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barbosa</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Bourguignon</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Arruda</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Jacques</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Serpa</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Calil</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Barbosa</surname>
                <given-names>LFM</given-names>
              </name>
            </person-group>
            <article-title>Anthracycline-associated cardiotoxicity in adults: systematic review on the cardioprotective role of beta-blockers.</article-title>
            <source>Rev Assoc Med Bras (1992)</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>64</volume>
            <issue>8</issue>
            <fpage>745</fpage>
            <page-range>745-754</page-range>
            <pub-id pub-id-type="pmid">30673046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17663.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prasanna</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Renu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Valsala Gopalakrishnan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>New molecular and biochemical insights of doxorubicin-induced hepatotoxicity.</article-title>
            <source>Life Sci</source>
            <year>2020</year>
            <month>Jun</month>
            <day>01</day>
            <volume>250</volume>
            <fpage>117599</fpage>
            <pub-id pub-id-type="pmid">32234491</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17663.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Slivnick</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vallakati</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Addison</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wallner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tong</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Personalized Approach to Cancer Treatment-Related Cardiomyopathy.</article-title>
            <source>Curr Heart Fail Rep</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>43</fpage>
            <page-range>43-55</page-range>
            <pub-id pub-id-type="pmid">32125627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17663.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pituskin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Haykowsky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McNeely</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mackey</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chua</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Paterson</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Rationale and design of the multidisciplinary team IntervenTion in cArdio-oNcology study (TITAN).</article-title>
            <source>BMC Cancer</source>
            <year>2016</year>
            <month>Sep</month>
            <day>15</day>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>733</fpage>
            <pub-id pub-id-type="pmid">27629548</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
